Complaints, Adverse Events, and UADE Escalation in Device Studies

Operational intake in a device study may receive the same issue through several channels: a site email, shipment query, technical-support call, complaint form, monitoring report, or direct communication from a subject.

The intake process must recognize potential safety information wherever it appears. It should not require the reporter to use the correct terminology before escalation begins.

Complaints, Adverse Events and UADEs Are Not Interchangeable

A complaint may concern device identity, quality, reliability, safety, effectiveness or performance. An adverse event is an unfavorable medical occurrence in a study subject, whether or not it is initially attributed to the device.

An unanticipated adverse device effect, or UADE, is a regulatory safety category requiring sponsor evaluation. Operational personnel should not make the final determination unless that responsibility has been formally delegated.

Capture the Minimum Available Facts

The intake workflow should capture the minimum available facts, including the reporter and site, subject identifier, device and lot or serial number, event description, outcome, dates, device availability, and any immediate action taken.

The reporter’s original wording should be preserved, the receipt time documented, and missing information pursued without delaying escalation.

Escalate Potential Safety Events Immediately

Potentially serious, life-threatening, unexpected or device-related events should be transmitted immediately to the sponsor’s designated safety contact and clinical team.

Device complaints should also enter the applicable quality-system pathway. Linked records should prevent either the clinical-safety process or the complaint process from assuming that the other owns follow-up.

The Sponsor Retains Medical and Regulatory Responsibility

The sponsor retains responsibility for medical and regulatory assessment, including seriousness, causality, expectedness, UADE status, trend significance, study impact and required notifications.

Operational intake supports that assessment by ensuring the sponsor receives complete, accurate and traceable information quickly. It does not replace the sponsor’s clinical or regulatory judgment.

Regulatory Deadlines Require Faster Internal Escalation

Investigators must report a UADE to the sponsor and reviewing Institutional Review Board—the U.S. term for an ethics committee—as soon as possible and no later than 10 working days after learning of it.

The sponsor must immediately evaluate the effect and report the evaluation results to FDA, reviewing IRBs and participating investigators within 10 working days after first receiving notice.

Operational intake therefore needs much faster internal targets than the regulatory deadline so the sponsor has sufficient time to investigate, evaluate and report.

Establish Controlled Intake and Escalation Channels

MDD Studies can establish controlled intake channels, escalation matrices, safety-contact coverage, complaint-to-event record linking, device-return coordination and reconciliation controls.

This helps the sponsor receive complete and traceable information quickly while preserving the sponsor’s authority over clinical-safety decisions and regulatory reporting.